Efficacy of palifermin in the treatment of oral mucositis in non-hematopoietic stem cell transplant pediatric patients: experience of a single tertiary hospital
Abstract Background Severe oral mucositis (OM) is one of the adverse events post-chemotherapy, radiation, and stem cell transplantation with major clinical and economic impact. The management of severe OM remains challenging. This study aimed to look for the benefit and clinical impact of palifermin...
Saved in:
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SpringerOpen
2024-12-01
|
| Series: | Journal of the Egyptian National Cancer Institute |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s43046-024-00247-x |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850136926640668672 |
|---|---|
| author | Hasna Hamzi Amal Binhassan Amal Najmeldin Ebtsam Alhariri Bodour Elhussein Nour Althibani Ahmad Alenazi Shahad Alsharif Mohammad Alshahrani Omar Alsharif Nawaf Alkhayat Yasser Elborai |
| author_facet | Hasna Hamzi Amal Binhassan Amal Najmeldin Ebtsam Alhariri Bodour Elhussein Nour Althibani Ahmad Alenazi Shahad Alsharif Mohammad Alshahrani Omar Alsharif Nawaf Alkhayat Yasser Elborai |
| author_sort | Hasna Hamzi |
| collection | DOAJ |
| description | Abstract Background Severe oral mucositis (OM) is one of the adverse events post-chemotherapy, radiation, and stem cell transplantation with major clinical and economic impact. The management of severe OM remains challenging. This study aimed to look for the benefit and clinical impact of palifermin for mucositis among the non-transplanted pediatric cancer population. Methods This is a descriptive retrospective study extended from 2016 to 2020 at Prince Sultan Military Medical City (PSMMC), in Saudi Arabia. During this period all pediatric patients (< 14 years of age) on chemotherapy and complicated by severe OM that required palifermin (35 courses), as off-labeled medication, were analyzed looking for the clinical demographics, primary diagnosis, chemotherapy agents used, effectiveness, and tolerability of palifermin. Results A total of 29 patients with severe OM received 35 palifermin courses. All of them received 60 mcg/kg/day IV for 3 consecutive days. 20% of them have acute lymphoblastic leukemia (ALL). We noticed that 60% of severe OM required palifermin post anthracycline while high-dose methotrexate aggravates the risk in 40% of them. Only 25.7% of the patients required TPN for a median duration of 5 days and 54.3% of them received opioids for a median duration of 4 days. Twenty patients (57.1%) had used antibiotics, 4 patients were on antifungal medication and 1 patient was on anti-viral medication concomitant with antibiotics. Conclusion Palifermin is safe and well tolerated and shows some effect in non-hematopoietic stem cell transplant pediatric patients with severe oral mucositis post-intensified chemotherapy or radiation therapy. |
| format | Article |
| id | doaj-art-cb4af0d89e3a47b197d2a3b78de2dd93 |
| institution | OA Journals |
| issn | 2589-0409 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | SpringerOpen |
| record_format | Article |
| series | Journal of the Egyptian National Cancer Institute |
| spelling | doaj-art-cb4af0d89e3a47b197d2a3b78de2dd932025-08-20T02:30:59ZengSpringerOpenJournal of the Egyptian National Cancer Institute2589-04092024-12-013611510.1186/s43046-024-00247-xEfficacy of palifermin in the treatment of oral mucositis in non-hematopoietic stem cell transplant pediatric patients: experience of a single tertiary hospitalHasna Hamzi0Amal Binhassan1Amal Najmeldin2Ebtsam Alhariri3Bodour Elhussein4Nour Althibani5Ahmad Alenazi6Shahad Alsharif7Mohammad Alshahrani8Omar Alsharif9Nawaf Alkhayat10Yasser Elborai11Department of Pediatric Hematology/Oncology, Prince Sultan Military Medical CityDepartment of Pediatric Hematology/Oncology, Prince Sultan Military Medical CityDepartment of Pediatric Hematology/Oncology, Prince Sultan Military Medical CityDepartment of Pediatric Hematology/Oncology, Prince Sultan Military Medical CityDepartment of Pediatric Hematology/Oncology, Prince Sultan Military Medical CityDepartment of Pediatric Hematology/Oncology, Prince Sultan Military Medical CityDepartment of Pediatric Hematology/Oncology, Prince Sultan Military Medical CityDepartment of Pediatric, Alyamamah HospitalDepartment of Pediatric Hematology/Oncology, Prince Sultan Military Medical CityDepartment of Pediatric Hematology/Oncology, Prince Sultan Military Medical CityDepartment of Pediatric Hematology/Oncology, Prince Sultan Military Medical CityDepartment of Pediatric Hematology/Oncology, Prince Sultan Military Medical CityAbstract Background Severe oral mucositis (OM) is one of the adverse events post-chemotherapy, radiation, and stem cell transplantation with major clinical and economic impact. The management of severe OM remains challenging. This study aimed to look for the benefit and clinical impact of palifermin for mucositis among the non-transplanted pediatric cancer population. Methods This is a descriptive retrospective study extended from 2016 to 2020 at Prince Sultan Military Medical City (PSMMC), in Saudi Arabia. During this period all pediatric patients (< 14 years of age) on chemotherapy and complicated by severe OM that required palifermin (35 courses), as off-labeled medication, were analyzed looking for the clinical demographics, primary diagnosis, chemotherapy agents used, effectiveness, and tolerability of palifermin. Results A total of 29 patients with severe OM received 35 palifermin courses. All of them received 60 mcg/kg/day IV for 3 consecutive days. 20% of them have acute lymphoblastic leukemia (ALL). We noticed that 60% of severe OM required palifermin post anthracycline while high-dose methotrexate aggravates the risk in 40% of them. Only 25.7% of the patients required TPN for a median duration of 5 days and 54.3% of them received opioids for a median duration of 4 days. Twenty patients (57.1%) had used antibiotics, 4 patients were on antifungal medication and 1 patient was on anti-viral medication concomitant with antibiotics. Conclusion Palifermin is safe and well tolerated and shows some effect in non-hematopoietic stem cell transplant pediatric patients with severe oral mucositis post-intensified chemotherapy or radiation therapy.https://doi.org/10.1186/s43046-024-00247-xPaliferminOral mucositisPediatric malignancyHematopoietic stem cell transplant |
| spellingShingle | Hasna Hamzi Amal Binhassan Amal Najmeldin Ebtsam Alhariri Bodour Elhussein Nour Althibani Ahmad Alenazi Shahad Alsharif Mohammad Alshahrani Omar Alsharif Nawaf Alkhayat Yasser Elborai Efficacy of palifermin in the treatment of oral mucositis in non-hematopoietic stem cell transplant pediatric patients: experience of a single tertiary hospital Journal of the Egyptian National Cancer Institute Palifermin Oral mucositis Pediatric malignancy Hematopoietic stem cell transplant |
| title | Efficacy of palifermin in the treatment of oral mucositis in non-hematopoietic stem cell transplant pediatric patients: experience of a single tertiary hospital |
| title_full | Efficacy of palifermin in the treatment of oral mucositis in non-hematopoietic stem cell transplant pediatric patients: experience of a single tertiary hospital |
| title_fullStr | Efficacy of palifermin in the treatment of oral mucositis in non-hematopoietic stem cell transplant pediatric patients: experience of a single tertiary hospital |
| title_full_unstemmed | Efficacy of palifermin in the treatment of oral mucositis in non-hematopoietic stem cell transplant pediatric patients: experience of a single tertiary hospital |
| title_short | Efficacy of palifermin in the treatment of oral mucositis in non-hematopoietic stem cell transplant pediatric patients: experience of a single tertiary hospital |
| title_sort | efficacy of palifermin in the treatment of oral mucositis in non hematopoietic stem cell transplant pediatric patients experience of a single tertiary hospital |
| topic | Palifermin Oral mucositis Pediatric malignancy Hematopoietic stem cell transplant |
| url | https://doi.org/10.1186/s43046-024-00247-x |
| work_keys_str_mv | AT hasnahamzi efficacyofpalifermininthetreatmentoforalmucositisinnonhematopoieticstemcelltransplantpediatricpatientsexperienceofasingletertiaryhospital AT amalbinhassan efficacyofpalifermininthetreatmentoforalmucositisinnonhematopoieticstemcelltransplantpediatricpatientsexperienceofasingletertiaryhospital AT amalnajmeldin efficacyofpalifermininthetreatmentoforalmucositisinnonhematopoieticstemcelltransplantpediatricpatientsexperienceofasingletertiaryhospital AT ebtsamalhariri efficacyofpalifermininthetreatmentoforalmucositisinnonhematopoieticstemcelltransplantpediatricpatientsexperienceofasingletertiaryhospital AT bodourelhussein efficacyofpalifermininthetreatmentoforalmucositisinnonhematopoieticstemcelltransplantpediatricpatientsexperienceofasingletertiaryhospital AT nouralthibani efficacyofpalifermininthetreatmentoforalmucositisinnonhematopoieticstemcelltransplantpediatricpatientsexperienceofasingletertiaryhospital AT ahmadalenazi efficacyofpalifermininthetreatmentoforalmucositisinnonhematopoieticstemcelltransplantpediatricpatientsexperienceofasingletertiaryhospital AT shahadalsharif efficacyofpalifermininthetreatmentoforalmucositisinnonhematopoieticstemcelltransplantpediatricpatientsexperienceofasingletertiaryhospital AT mohammadalshahrani efficacyofpalifermininthetreatmentoforalmucositisinnonhematopoieticstemcelltransplantpediatricpatientsexperienceofasingletertiaryhospital AT omaralsharif efficacyofpalifermininthetreatmentoforalmucositisinnonhematopoieticstemcelltransplantpediatricpatientsexperienceofasingletertiaryhospital AT nawafalkhayat efficacyofpalifermininthetreatmentoforalmucositisinnonhematopoieticstemcelltransplantpediatricpatientsexperienceofasingletertiaryhospital AT yasserelborai efficacyofpalifermininthetreatmentoforalmucositisinnonhematopoieticstemcelltransplantpediatricpatientsexperienceofasingletertiaryhospital |